Invitrogen to migrate to Novell's SUSE Linux Enterprise

Wed. July 02, 2008; Posted: 08:58 AM

Jul 02, 2008 (TELECOMWORLDWIRE via COMTEX) -- NOVL | Quote | Chart | News | PowerRating -- Novell Inc (Nasdaq: NOVL), a software company and distributor of Linux value-added operating systems, announced on 2 July that Invitrogen, a life sciences technologies company, has selected Novell's SUSE Linux Enterprise as the firm's core operating system.

Invitrogen will migrate existing platforms to SUSE, using VMWare virtualisation to support existing software based on alternative operating systems. The inbuilt support of SUSE's Virtual Machine Interface (VMI) enabled kernel was an important factor in the decision to use SUSE, according to John Merrit of Invitrogen.

The firm, which has interests in 70 countries and offers some 35,000 products and services, currently uses a mix of Oracles databases, web servers and PeopleSoft ERP applications on a mixture of Windows and UNIX based HP servers.

Invitrogen have the assistance of PlateSpin, a Novell services management company, to help with the physical-to-physical migration and also move existing Windows and UNIX implementations into virtualised environments.

Comments on this story may be sent to tww.feedback@m2.com

For full details on Novell Inc (NOVL) click here. Novell Inc (NOVL) has Short Term PowerRatings of 4. Details on Novell Inc (NOVL) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.